Cargando…

Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance

SIMPLE SUMMARY: Glucose metabolic reprogramming is a process in which cells alter the way that glucose is utilized. In breast cancer, cells can undergo this process to fuel their growth, acquire drug resistance, and become metastatic. Scientists have been studying this process to identify new target...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Pan, Wang, Wenzhou, Sheldon, Marisela, Sun, Yutong, Yao, Fan, Ma, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341343/
https://www.ncbi.nlm.nih.gov/pubmed/37444501
http://dx.doi.org/10.3390/cancers15133390
_version_ 1785072239788425216
author Lei, Pan
Wang, Wenzhou
Sheldon, Marisela
Sun, Yutong
Yao, Fan
Ma, Li
author_facet Lei, Pan
Wang, Wenzhou
Sheldon, Marisela
Sun, Yutong
Yao, Fan
Ma, Li
author_sort Lei, Pan
collection PubMed
description SIMPLE SUMMARY: Glucose metabolic reprogramming is a process in which cells alter the way that glucose is utilized. In breast cancer, cells can undergo this process to fuel their growth, acquire drug resistance, and become metastatic. Scientists have been studying this process to identify new targets for breast cancer treatment. By understanding what enzymes and pathways are involved, researchers may be able to develop drugs that specifically target these pathways, ultimately leading to more effective and less toxic treatments for breast cancer in the future. ABSTRACT: The involvement of glucose metabolic reprogramming in breast cancer progression, metastasis, and therapy resistance has been increasingly appreciated. Studies in recent years have revealed molecular mechanisms by which glucose metabolic reprogramming regulates breast cancer. To date, despite a few metabolism-based drugs being tested in or en route to clinical trials, no drugs targeting glucose metabolism pathways have yet been approved to treat breast cancer. Here, we review the roles and mechanisms of action of glucose metabolic reprogramming in breast cancer progression and drug resistance. In addition, we summarize the currently available metabolic inhibitors targeting glucose metabolism and discuss the challenges and opportunities in targeting this pathway for breast cancer treatment.
format Online
Article
Text
id pubmed-10341343
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103413432023-07-14 Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance Lei, Pan Wang, Wenzhou Sheldon, Marisela Sun, Yutong Yao, Fan Ma, Li Cancers (Basel) Review SIMPLE SUMMARY: Glucose metabolic reprogramming is a process in which cells alter the way that glucose is utilized. In breast cancer, cells can undergo this process to fuel their growth, acquire drug resistance, and become metastatic. Scientists have been studying this process to identify new targets for breast cancer treatment. By understanding what enzymes and pathways are involved, researchers may be able to develop drugs that specifically target these pathways, ultimately leading to more effective and less toxic treatments for breast cancer in the future. ABSTRACT: The involvement of glucose metabolic reprogramming in breast cancer progression, metastasis, and therapy resistance has been increasingly appreciated. Studies in recent years have revealed molecular mechanisms by which glucose metabolic reprogramming regulates breast cancer. To date, despite a few metabolism-based drugs being tested in or en route to clinical trials, no drugs targeting glucose metabolism pathways have yet been approved to treat breast cancer. Here, we review the roles and mechanisms of action of glucose metabolic reprogramming in breast cancer progression and drug resistance. In addition, we summarize the currently available metabolic inhibitors targeting glucose metabolism and discuss the challenges and opportunities in targeting this pathway for breast cancer treatment. MDPI 2023-06-28 /pmc/articles/PMC10341343/ /pubmed/37444501 http://dx.doi.org/10.3390/cancers15133390 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lei, Pan
Wang, Wenzhou
Sheldon, Marisela
Sun, Yutong
Yao, Fan
Ma, Li
Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
title Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
title_full Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
title_fullStr Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
title_full_unstemmed Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
title_short Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
title_sort role of glucose metabolic reprogramming in breast cancer progression and drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341343/
https://www.ncbi.nlm.nih.gov/pubmed/37444501
http://dx.doi.org/10.3390/cancers15133390
work_keys_str_mv AT leipan roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance
AT wangwenzhou roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance
AT sheldonmarisela roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance
AT sunyutong roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance
AT yaofan roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance
AT mali roleofglucosemetabolicreprogramminginbreastcancerprogressionanddrugresistance